Why Testosterone Matters for Women: Hormone Therapy, Menopause, Libido, and Modern Women's Health

What Testosterone Does in the Female Body

Testosterone is not a "male hormone" that women happen to carry in small amounts. It is an essential androgen produced in the ovaries, the adrenal glands, and through peripheral conversion of androstenedione in fat and skin tissue. Women produce roughly 100 to 400 micrograms of testosterone daily, a quantity comparable on a per-kilogram basis to what men produce 1.

Androgen Receptors Throughout Female Tissue

Androgen receptors appear in the brain, vaginal wall, clitoris, bone, skeletal muscle, breast tissue, and skin. This distribution explains why testosterone deficiency produces a wide symptom cluster, not a single complaint. The North American Menopause Society notes that androgens act "both directly through androgen receptors and indirectly through conversion to estrogens" in female tissue 2.

The Production Decline Over Time

Total testosterone in women peaks around age 20 to 25. By the mid-40s, levels have fallen by roughly 50% compared to that peak 3. Unlike estrogen, which drops sharply at menopause, testosterone follows a more gradual slope beginning in the late 20s. Surgical menopause (bilateral oophorectomy) causes an immediate 50% drop in testosterone production because the ovaries account for approximately half of total output 4.

Energy, Muscle, and Bone

Beyond libido, testosterone supports skeletal muscle protein synthesis and activates androgen receptors in osteoblasts, the cells that build new bone. Low androgen levels in postmenopausal women have been associated with lower bone mineral density independent of estrogen status 5. A 2003 analysis in the Journal of Clinical Endocrinology and Metabolism found that free testosterone was a significant positive predictor of lumbar spine bone mineral density in postmenopausal women even after controlling for estrogen 6.

How Menopause Changes Testosterone Levels

Menopause disrupts the hormonal axis in ways that go well beyond estrogen withdrawal. The conversation about menopause has historically centered on estrogen and progesterone, but the androgenic changes are clinically significant and often under-discussed.

Ovarian vs. Adrenal Contributions

Before menopause, the ovaries contribute about 25% of circulating testosterone directly and another 25% through androstenedione conversion. The adrenal glands supply the rest. After natural menopause, ovarian stromal cells continue producing testosterone, though at reduced rates. Adrenal androgen output (via DHEA and DHEA-S) also declines with age, independent of ovarian function. By the late 50s, DHEA-S levels may be 60 to 80% lower than peak young-adult values 7.

Surgical Menopause: A Sharper Drop

Women who undergo bilateral oophorectomy experience a more abrupt testosterone decline than women entering natural menopause. Studies show that oophorectomized women report significantly higher rates of sexual dysfunction and reduced well-being compared to naturally menopausal women at similar estrogen levels 8. This finding helped establish the clinical rationale for post-oophorectomy testosterone replacement.

Sex Hormone Binding Globulin: The Hidden Variable

Oral estrogen therapy raises sex hormone binding globulin (SHBG), which binds testosterone and reduces free (biologically active) testosterone. A woman who starts oral estrogen-only HRT may experience a further effective reduction in free testosterone even if her total testosterone stays stable 9. Transdermal estrogen produces a smaller rise in SHBG, which is one clinical reason to prefer the transdermal route in women who are also at risk for androgen insufficiency.

Testosterone and Female Sexual Function

The strongest evidence for testosterone therapy in women centers on sexual function, specifically hypoactive sexual desire disorder (HSDD). HSDD is defined as persistent or recurrent absence of sexual desire causing personal distress. It affects an estimated 10% of all women and up to 40% of postmenopausal women depending on the population studied 10.

The APHRODITE Trial

The APHRODITE trial randomized 814 naturally menopausal women with HSDD to a transdermal testosterone patch (300 mcg/day) or placebo. At 52 weeks, the testosterone group reported a mean increase of 2.1 satisfying sexual events per month versus 0.98 in the placebo group, a 59% advantage 11. The authors concluded that transdermal testosterone "significantly improved sexual function in naturally menopausal women with HSDD."

The ADORE Trial and Surgical Menopause

The ADORE trial (N=272) examined the same 300 mcg/day transdermal patch in surgically menopausal women taking concomitant estrogen therapy. At 24 weeks, women on testosterone reported 1.56 more satisfying sexual events per month compared to baseline, versus 0.73 in the placebo group (P<0.001) 12. Both trials showed no significant changes in lipid panels, liver enzymes, or cardiovascular events at their respective endpoints.

Beyond the Patch: Compounded and Off-Label Options

Intrinsa, the 300 mcg/day patch studied in APHRODITE, was approved in Europe but withdrawn from the European market in 2012 for commercial reasons, not safety. No testosterone product carries FDA approval for use in women in the United States as of 2025. Clinicians prescribe off-label formulations including low-dose testosterone gels (1% testosterone gel at 1/10th the male dose, approximately 0.5 to 1 mg/day) and compounded creams. The 2019 Global Consensus Position Statement, co-authored by representatives from the Endocrine Society, the British Menopause Society, the International Menopause Society, and the North American Menopause Society, states: "There is sufficient evidence to support the use of testosterone for the treatment of HSDD in postmenopausal women" 13.

Mood, Cognition, and Energy: What the Evidence Shows

The effect of testosterone on mood, cognitive sharpness, and fatigue in women is biologically plausible, given androgen receptor distribution in the prefrontal cortex and hippocampus. The clinical evidence is less definitive here than it is for sexual function, but several studies point in a consistent direction.

Mood and Well-Being Data

A randomized trial by Shifren et al. Published in the New England Journal of Medicine (N=75, surgically menopausal women) found that 300 mcg/day transdermal testosterone significantly improved scores on the Brief Index of Sexual Functioning for Women, with secondary improvements in psychological well-being and depressed mood compared to placebo 14. The mood effects were measured on the Psychological General Well-Being Index, with testosterone-group scores rising by 8 points compared to 3 points in the placebo group.

Cognitive Function

Animal studies show testosterone modulates dopaminergic and serotonergic pathways relevant to attention and memory. Human data remain mixed. A 2004 review in the Journal of Clinical Endocrinology and Metabolism found suggestive but not conclusive evidence that androgen supplementation improves verbal memory and spatial cognition in postmenopausal women 15. Larger, longer trials are needed before cognitive benefits can be stated as a confirmed indication.

Fatigue and Lean Body Mass

Testosterone stimulates erythropoiesis and muscle protein synthesis. In a 24-week randomized trial of 34 women with adrenal insufficiency (a model of combined androgen and corticosteroid deficiency), DHEA supplementation (50 mg/day, which converts partly to testosterone) improved self-reported fatigue scores by 30% versus placebo 16.

Diagnosing Androgen Insufficiency in Women

There is no universally agreed lower threshold for "normal" female testosterone. The 2014 Endocrine Society Clinical Practice Guideline on androgen therapy in women explicitly stated that the evidence is insufficient to define a female androgen deficiency syndrome by laboratory values alone 17. Diagnosis is clinical and symptom-driven, supported by lab testing.

What to Measure

Clinicians typically order total testosterone, free testosterone (calculated or by equilibrium dialysis), and SHBG. Total testosterone values below 15 ng/dL in premenopausal women or below 10 ng/dL in postmenopausal women are often cited as consistent with low androgen states, though individual labs vary. DHEA-S gives an adrenal androgen picture and declines predictably with age regardless of ovarian function 18.

Assay Limitations

Standard immunoassay testosterone tests, designed and validated for male reference ranges, perform poorly at the low concentrations typical of women. The Endocrine Society recommends liquid chromatography-tandem mass spectrometry (LC-MS/MS) for accurate female testosterone measurement 17. Many commercial labs now offer this methodology, though it is not universally available.

A Clinical Framework for Evaluation

A structured approach for women presenting with low libido, fatigue, and mood symptoms might include: (1) ruling out thyroid dysfunction, iron deficiency anemia, and depression as primary causes; (2) reviewing current medications (oral contraceptives and oral estrogen raise SHBG and lower free testosterone); (3) ordering LC-MS/MS testosterone, free testosterone, SHBG, and DHEA-S; and (4) using validated symptom tools such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS) to quantify distress. Treatment decisions should rest on the full clinical picture, not on a single lab value.

Testosterone Therapy: Formulations, Dosing, and Monitoring

No FDA-approved female testosterone product exists in the United States as of mid-2025. Clinicians use one of three practical approaches.

Off-Label Male Formulations at Low Dose

The most common practice is applying a fraction of a standard male 1% testosterone gel (Androgel, Testim) or a 1.62% gel to achieve a daily dose of approximately 0.5 to 2 mg of testosterone. This contrasts with the 25 to 75 mg doses used in men. At these doses, serum testosterone should remain within the normal premenopausal female range (roughly 15 to 70 ng/dL free, or total testosterone <150 ng/dL) 13.

Compounded Testosterone Creams

Compounding pharmacies prepare 0.5% to 2% testosterone cream or gel in doses calibrated for women. Quality and bioavailability vary between pharmacies. The 2019 Global Consensus Position Statement cautions that "compounded testosterone preparations are not recommended as first-line treatment due to lack of regulatory oversight and inconsistent dosing" 13.

Monitoring Schedule

The 2019 Consensus recommends checking testosterone levels 4 to 6 weeks after starting therapy and every 6 months thereafter. If total testosterone rises above 150 ng/dL, the dose should be reduced. Signs of androgen excess to monitor include acne, increased facial or body hair (hirsutism), scalp hair thinning, and voice changes. Lipid panels and hematocrit monitoring every 12 months are considered standard 13.

Safety: What the Trials and Guidelines Say

Short-term trials lasting 24 to 52 weeks have not identified cardiovascular harm from testosterone at physiologic female doses. The APHRODITE trial showed no significant differences in lipid profiles between the testosterone patch and placebo groups at 52 weeks 11. Long-term data beyond 2 years are limited, which is one reason guidelines restrict the indication to postmenopausal HSDD rather than broader preventive uses.

Breast Cancer: The Uncertain Picture

Estrogen's relationship with breast cancer risk is well-characterized. Testosterone's role is more complex. Androgens may exert anti-proliferative effects on breast tissue via androgen receptors, while also serving as a substrate for aromatization to estrogen. The 2019 Global Consensus Statement noted that "there are insufficient data to conclude that testosterone therapy increases breast cancer risk" but called for continued surveillance and cautioned against use in women with active or recent breast cancer 13.

A 2021 systematic review and meta-analysis in Menopause (N=8 observational studies, over 240,000 women) found no statistically significant association between endogenous testosterone levels and breast cancer incidence in postmenopausal women 19.

Virilization Risk

Virilization at physiologic replacement doses is uncommon but not impossible. Clitoral enlargement and permanent voice changes are rare at doses maintaining testosterone within the premenopausal female range. Acne and mild hirsutism are more common and generally reversible with dose reduction 13.

Oral Contraceptives, SHBG, and the Libido Paradox

One underappreciated clinical scenario involves women on combined oral contraceptives (COCs) who report loss of libido, vaginal dryness, and fatigue. COCs suppress ovarian testosterone production by inhibiting LH and simultaneously raise SHBG (because of their ethinyl estradiol component), compressing free testosterone from both ends. A 2006 study in the Journal of Sexual Medicine found that women on COCs had SHBG levels approximately 4 times higher than naturally cycling women, persisting for months after pill discontinuation 20. Clinicians should measure SHBG and free testosterone in this group before attributing symptoms to psychological causes.

The Regulatory Gap and What It Means for Patients

The absence of an FDA-approved female testosterone product is not a reflection of evidence. It reflects commercial decisions and a historical tendency to frame female sexual dysfunction as primarily psychological rather than hormonal. The Endocrine Society's 2014 guideline called the field "underserved" and recommended that "future clinical trials should evaluate the safety and efficacy of testosterone therapy in women" 17.

Several pharmaceutical companies have been developing candidate products. LibiGel (BioSante), a transdermal testosterone gel for women, completed a Phase 3 trial (BLOOM trial, N=3,656) that did not meet its primary endpoint for satisfying sexual events, though secondary endpoints showed significant improvements in sexual desire scores 21. The FDA's decision not to approve Intrinsa in 2004 cited concerns about long-term cardiovascular and breast cancer data, though the agency acknowledged short-term efficacy.